Companion diagnostic testing
Nonsmall cell lung cancer (NSCLC)


Minor changes: 2 April 2020

Copyright: 2019, PathologyOutlines.com, Inc.

See also: Lung-adenocarcinoma, Lung-squamous cell carcinoma

Sponsors: Company A

This is a new chapter. Tell us what additional information you want to see by clicking here

Nat Pernick, M.D.
Page views in 2019: 69
Page views in 2020 to date: 545
Cite this page: Pernick N. Companion diagnostic testing - Nonsmall cell lung cancer (NSCLC). PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/companionlung.html. Accessed August 11th, 2020.
Contact Sponsor A with your questions
    Pathologists: contact Sponsor A with questions about Companion Diagnostic Testing at xxx/yyy-zzz or Email

    Patients: contact Sponsor A with questions at xxx/yyy-zzz or Email
Definition / general
  • Based on NCCN guidelines, version 7.2019, initial step for advanced or metastatic disease is establishing histologic subtype and obtaining tissue for molecular testing (NCCN Guidelines for NSCLC (login required), PDF page 37)
Adenocarcinoma, Large cell, NSCLC-NOS
  • Recommended molecular testing:
  • Broad molecular profiling is recommended to identify rare drive mutations, either because they may have effective drugs or support eligibility in specific clinical trials
Squamous cell carcinoma
  • Consider EGFR mutation and ALK testing for never smokers, small biopsies or mixed histology
  • Consider ROS1 and BRAF testing in small biopsies or mixed histology
  • PDL1
  • Broad molecular profiling is recommended to identify rare drive mutations, either because they may have effective drugs or support eligibility in specific clinical trials
Back to top